ViGeneron Announces FDA Clearance of IND for Novel mRNA Trans-Splicing Gene Therapy VG801 to Treat Stargardt Disease and Other ABCA4-Linked Retinal Dystrophies
18 déc. 2024 08h00 HE
|
ViGeneron GmbH
VG801 is the first FDA IND clearance for novel mRNA trans-splicing gene therapy, delivering the full-length functional ABCA4 gene to target the genetic root cause of retinal dystrophies associated...
ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 for the Intravitreal Treatment of Retinitis Pigmentosa
10 avr. 2024 05h03 HE
|
ViGeneron GmbH
VG901 is the first and only clinical-stage therapy designed to deliver a functional CNGA1 gene to retinal photoreceptor target cells in retinitis pigmentosa patientsVG901, using ViGeneron’s...
Nature Communications publication reveals highly efficient AAV delivery of large genes using ViGeneron’s REVeRT technology
25 oct. 2023 08h00 HE
|
ViGeneron GmbH
REVeRT, a dual vector approach based on mRNA trans-splicing, enables delivery of genes larger than the usual AAV packaging size in various tissuesPotential to address prevalent inherited diseases...
ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases
26 avr. 2022 03h00 HE
|
ViGeneron GmbH
The companies agree a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vgAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases ...
ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target
06 avr. 2022 03h00 HE
|
ViGeneron GmbH
Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exclusive license to develop and commercialize the gene therapy productViGeneron is...
ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy
18 janv. 2021 02h00 HE
|
ViGeneron GmbH
MUNICH, Germany, Jan. 18, 2021 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV)...
ViGeneron signs global collaboration agreement for ophthalmic gene therapy development
05 janv. 2021 02h00 HE
|
ViGeneron GmbH
Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional targetThe companies will use ViGeneron’s proprietary vgAAV...
ViGeneron announces closing of series A financing to drive development of next generation gene therapy pipeline
28 nov. 2019 02h00 HE
|
ViGeneron GmbH
Funds will advance development of ViGeneron’s next-generation ophthalmic gene therapy pipeline and vector platforms Round attracts two esteemed investors - WuXi AppTec and Sequoia Capital China known...